Predictive technology to impact clinical trial design and outcomes
Available for research use only and protected by 3 patents, QyPredict® has the potential to improve targeted patient selection in clinical trials and prediction of disease progression in patients.
QyPredict® is the future, and the future is here.
Being developed for automated prediction of clinical disease progression based on a patient’s MRI and clinical data and the use of robust algorithms scanning our normative dataset of 10,000 brain scan images, QyPredict® aims to transform clinical trials and patient care.
The ability to predict the onset of a CNS disease is within our reach. That’s why Qynapse and our team of world-renowned neuroscience experts and principal investigators are dedicated to the continued development of QyPredict®.
For clinical trials, QyPredict® equips researchers with the ability to adjust patient selection and predict clinical progression, increasing the likelihood of trial success.
For physicians, we are exploring the potential to predict a patient’s individual disease trajectory, which would transform and improve timely intervention and treatment plans, potentially significantly improving quality of life and outcomes.
Olivier Courrèges
Founder & CEO | Qynapse
When someone you love is declining mentally, there’s nothing worse than not having a clear diagnosis as to why. That’s why Qynapse is on a mission to transform time to diagnosis and the accuracy for diagnosis for CNS disease.
Srinivas Peddi, MD
Radiologist & Board Member | Tower Imaging Medical Group
When you remove air from a ball, it’s hard to figure that out until it’s lost a lot of volume. But if we had a tool that would let us measure more precisely? That’s super helpful. And that’s what Qynapse provides.
Diane Souza
Former CEO | UnitedHealthcare Specialty Benefits
Payers have developed very sophisticated systems and data sets to help their members, healthcare providers and teams make better decisions about healthcare. What Qynapse provides further enhances that decision making, resulting from the whole being greater than the sum of the parts.
Bruno Dubois, MD, PhD
Professor of Neurology | Sorbonne University, Director of the Institute of Memory and Alzheimer’s Disease (IM2A) | Pitié Salpêtrière Hospital in Paris
In light of the recent breakthrough for Alzheimer’s patients – the approval of new treatment options by the FDA, Qynapse’s vision is becoming even more critical to advance the early detection of Alzheimer’s disease and to precisely monitor the therapy efficacy and safety.
David Merrill, MD, PhD
Director | Pacific Brain Health Center Pacific Neuroscience Institute
I’m excited to use QyScore® to quantify both volumetric and white matter integrity in our patients – bringing such an important layer of precision and objectivity to inform our clinical decisions.
Marwan N. Sabbagh
MD, FAAN, CCRI
Going from a diagnostic accuracy of 66-70% to better than 90% is today the most pressing topic for the Alzheimer’s disease community. I am glad to see innovative organizations like Qynapse leading the way and contributing to transform the diagnosis of Alzheimer’s disease.
Transform your Clinical Trial.
Qyscore® is a medical device software FDA-cleared – class II and CE-marked – class IIa.
Indications for Use in the U.S. (FDA): QyScore® is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures and lesions from a set of MR images. Volumetric data may be compared to reference percentile data. QyScore is not intended for use in clinical scenarios that require evaluation of the number of the white matter hyperintensities.
Indications for Use in Europe (CE): QyScore® is an advanced processing and visualization software for automatic labeling and volumetric quantification of segmented central nervous system structures for patients older than 18 years of age. The software is intended to be used by medical personnel or neuroimaging trained personnel to support diagnosis of central nervous system diseases.